Top

Published in:

01-12-2012

Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment

Authors: Evi S. Lianidou, Athina Markou, Areti Strati

Published in: Cancer and Metastasis Reviews | Issue 3-4/2012

Abstract

Blood testing using Circulating Tumor Cells (CTCs) has emerged as one of the hottest fields in cancer diagnosis. Research on CTCs present nowadays a challenge, as these cells are well defined targets for understanding tumour biology and improving cancer treatment. The presence of tumor cells in patient’s bone marrow or peripheral blood is an early indicator of metastasis and may signal tumor spread sooner than clinical symptoms appear and imaging results confirm a poor prognosis. CTC enumeration can serve as a “liquid biopsy” and an early marker to assess response to systemic therapy. Definition of biomarkers based on comprehensive characterization of CTCs has a strong potential to be translated to individualized targeted treatments and spare breast cancer patients unnecessary and ineffective therapies but also to reduce the costs for the health system and to downsize the extent and length of clinical studies. In this review, we briefly summarize recent studies on the molecular characterization of circulating tumor cells in breast cancer and discuss challenges and promises of CTCs for individualized cancer treatment.

Pantel, K., Alix-Panabières, C., & Riethdorf, S. (2009). Cancer micrometastases. Nature Reviews Clinical Oncology, 6, 339–351.PubMedCrossRef

Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Pantel, K., et al. (2005). A pooled analysis of bone marrow micrometastasis in breast cancer. The New England Journal of Medicine, 353, 793–802.PubMedCrossRef

Stathopoulou, A., Vlachonikolis, I., Mavroudis, D., Perraki, M., Georgoulias, V., et al. (2002). Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. Journal of Clinical Oncology, 20, 3404–3412.PubMedCrossRef

Xenidis, N., Vlachonikolis, I., Mavroudis, D., Perraki, M., Stathopoulou, A., Lianidou, E., Georgoulias, V., et al. (2003). Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Annals of Oncology, 14, 849–855.PubMedCrossRef

Xenidis, N., Perraki, M., Kafousi, M., Apostolaki, S., Lianidou, E. S., Georgoulias, V., Mavroudis, D., et al. (2006). Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. Journal of Clinical Oncology, 24, 3756–3762.PubMedCrossRef

Ignatiadis, M., Kallergi, G., Ntoulia, M., Lianidou, E., Georgoulias, V., Mavroudis, D., et al. (2008). Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clinical Cancer Research, 14, 2593–2600.PubMedCrossRef

Ignatiadis, M., Xenidis, N., Perraki, M., Lianidou, E., Sotiriou, C., Georgoulias, V., Mavroudis, D., et al. (2007). Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. Journal of Clinical Oncology, 25, 5194–5202.PubMedCrossRef

Cristofanilli, M., Budd, G. T., Ellis, M. J., Allard, W. J., Terstappen, L. W., Hayes, D. F., et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. The New England Journal of Medicine, 351, 781–791.PubMedCrossRef

Xenidis, N., Ignatiadis, M., Apostolaki, S., Perraki, M., Georgoulias, V., Mavroudis, D., et al. (2009). Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. Journal of Clinical Oncology, 27, 2177–2184.PubMedCrossRef

10.

de Bono, J. S., Scher, H. I., Montgomery, R. B., Doyle, G. V., Terstappen, L. W., Pienta, K. J., Raghavan, D., et al. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research, 14, 6302–6309.PubMedCrossRef

11.

Scher, H. I., Jia, X., de Bono, J. S., Fleisher, M., Pienta, K. J., Raghavan, D., & Heller, G. (2009). Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer. A reanalysis of IMMC38 trial data. The Lancet Oncology, 10, 233–239.PubMedCrossRef

12.

Diamandis, E. P., Pantel, K., Scher, H. I., Terstappen, L., & Lianidou, E. (2011). Circulating cancer cells and their clinical applications. Clinical Chemistry, 57, 1478–1484.PubMedCrossRef

13.

Meng, S., Tripathy, D., Shete, S., Ashfaq, R., Haley, B., Uhr, J., et al. (2004). HER-2 gene amplification can be acquired as breast cancer progresses. Proceedings of the National Academy of Sciences of the United States of America, 101, 9393–9398.PubMedCrossRef

14.

Bozionellou, V., Mavroudis, D., Perraki, M., Stathopoulou, A., Lianidou, E., Georgoulias, V., et al. (2004). Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clinical Cancer Research, 10, 8185–8194.PubMedCrossRef

15.

Korkaya, H., & Wicha, M. S. (2009). HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clinical Cancer Research, 15, 1845–1847.PubMedCrossRef

16.

Maheswaran, S., Sequist, L. V., Nagrath, S., et al. (2008). Detection of mutations in EGFR in circulating lung-cancer cells. The New England Journal of Medicine, 359, 366–377.PubMedCrossRef

17.

Fehm, T., Braun, S., Muller, V., Janni, W., Naume, B., Pantel, K., Solomayer, E., et al. (2006). A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer, 107, 885–892.PubMedCrossRef

18.

Ring, A. E., Zabaglo, L., Ormerod, M. G., Smith, I. E., & Dowsett, M. (2005). Detection of circulating epithelial cells in the blood of patients with breast cancer. Comparison of three techniques. British Journal of Cancer, 92, 906–912.PubMedCrossRef

19.

Reinholz, M. M., Nibbe, A., Jonart, L. M., Houghton, R., Zehentner, B., Roche, P. C., Lingle, W. L., et al. (2005). Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clinical Cancer Research, 11, 3722–3732.PubMedCrossRef

20.

Stathopoulou, A., Gizi, A., Perraki, M., Apostolaki, S., Georgoulias, V., Lianidou, E. S., et al. (2003). Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the Lightcycler system. Clinical Cancer Research, 9, 5145–5151.PubMed

21.

Stathopoulou, A., Ntoulia, M., Perraki, M., Malamos, N., Georgoulias, V., Lianidou, E. S., et al. (2006). A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. International Journal of Cancer, 119, 1654–1659.CrossRef

22.

Raynor, M. P., Stephenson, S. A., Pittman, K. B., Walsh, D. C., Henderson, M. A., & Dobrovic, A. (2009). Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR. Journal of Hematology & Oncology, 2, 24–35.CrossRef

23.

Riethdorf, S., Fritsche, H., Müller, V., Cristofanilli, M., Pantel, K., et al. (2007). Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. A validation study of the Cell Search system. Clinical Cancer Research, 13, 920–928.PubMedCrossRef

24.

Kallergi, G., Markomanolaki, H., Strati, A., Lianidou, E. S., Georgoulias, V., Mavroudis, D., Agelaki, S., et al. (2009). Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Research, 11, R84.PubMedCrossRef

25.

Zheng, S., Lin, H., Liu, J. Q., Balic, M., Datar, R., Cote, R. J., & Tai, Y. C. (2007). Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. Journal of Chromatography. A, 1162, 154–161.PubMedCrossRef

26.

Nagrath, S., Sequist, L. V., Maheswaran, S., Kwak, E. L., Toner, M., et al. (2007). Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature, 450, 1235–1239.PubMedCrossRef

27.

Lianidou, E. S., & Markou, A. (2011). Circulating tumor cells (CTC) in breast cancer: detection systems, molecular characterization and future challenges. Clinical Chemistry, 57, 1242–1255.PubMedCrossRef

28.

Lianidou, E. S., & Markou, A. (2011). Circulating tumor cells as emerging tumor biomarkers in breast cancer. Clinical Chemistry and Laboratory Medicine, 49, 1579–1590.PubMedCrossRef

29.

Cao, S., Li, Y., Li, J., Li, C. F., Zhang, W., Yang, Z. Q., et al. (2010). Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer. Oncology Reports, 23, 423–428.PubMed

30.

Fehm, T., Hoffmann, O., Aktas, B., Becker, S., Solomayer, E. F., Wallwiener, D., et al. (2009). Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Research, 11, R59.PubMedCrossRef

31.

Fehm, T., Müller, V., Aktas, B., Janni, W., Schneeweiss, A., Stickeler, E., et al. (2010). HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Research and Treatment, 124, 403–412.PubMedCrossRef

32.

Tewes, M., Aktas, B., Welt, A., Mueller, S., Hauch, S., Kimmig, R., et al. (2009). Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Research and Treatment, 115, 581–590.PubMedCrossRef

33.

Riethdorf, S., Müller, V., Zhang, L., Rau, T., Loibl, S., Komor, M., et al. (2010). Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research, 16(9), 2634–2645.PubMedCrossRef

34.

Ignatiadis, M., Rothé, F., Chaboteaux, C., Durbecq, V., Rouas, G., Criscitiello, C., et al. (2011). HER2-positive circulating tumor cells in breast cancer. PloS One, 6, e15624.PubMedCrossRef

35.

Flores, L. M., Kindelberger, D. W., Ligon, A. H., Capelletti, M., Fiorentino, M., Loda, M., et al. (2010). Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. British Journal of Cancer, 102, 1495–1502.PubMedCrossRef

36.

Pestrin, M., Bessi, S., Galardi, F., Truglia, M., Biggeri, A., Biagioni, C., Cappadona, S., Biganzoli, L., Giannini, A., & Di Leo, A. (2009). Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Research and Treatment, 118(3), 523–530.PubMedCrossRef

37.

Sieuwerts, A. M., Mostert, B., Bolt-de Vries, J., Peeters, D., de Jongh, F. E., Stouthard, J. M., Dirix, L. Y., van Dam, P. A., Van Galen, A., de Weerd, V., Kraan, J., van der Spoel, P., Ramírez-Moreno, R., van Deurzen, C. H., Smid, M., Yu, J. X., Jiang, J., Wang, Y., Gratama, J. W., Sleijfer, S., Foekens, J. A., & Martens, J. W. (2011). mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clinical Cancer Research, 17(11), 3600–3618.PubMedCrossRef

38.

Punnoose, E. A., Atwal, S. K., Spoerke, J. M., Savage, H., Pandita, A., Yeh, R. F., Pirzkall, A., Fine, B. M., Amler, L. C., Chen, D. S., Lackner, MR. (2010). Molecular biomarker analyses using circulating tumor cells. PLoS One, 5(9).

39.

Aktas, B., Müller, V., Tewes, M., Zeitz, J., Kasimir-Bauer, S., Loehberg, C. R., Rack, B., Schneeweiss, A., & Fehm, T. (2011). Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecologic Oncology, 122(2), 356–360.PubMedCrossRef

40.

Banys, M., Krawczyk, N., Becker, S., Jakubowska, J., Staebler, A., Wallwiener, D., Fehm, T., & Rothmund, R. (2011). The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Research and Treatment, 132, 121–129.PubMedCrossRef

41.

Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial–mesenchymal transition. The Journal of Clinical Investigation, 119(6), 1420–1428.PubMedCrossRef

42.

Sleeman, J. P., & Thiery, J. P. (2011). SnapShot: the epithelial–mesenchymal transition. Cell, 145(1), 162.PubMedCrossRef

43.

Bonnomet, A., Brysse, A., Tachsidis, A., Waltham, M., Thompson, E. W., Polette, M., et al. (2010). Epithelial-to-mesenchymal transitions and circulating tumor cells. Journal of Mammary Gland Biology and Neoplasia, 15, 261–273.PubMedCrossRef

44.

Balic, M., Williams, A., Dandachi, N., & Cote, R. J. (2011). Micrometastasis: detection methods and clinical importance. Cancer Biomarkers, 9(1–6), 397–419.

45.

Balic, M., Lin, H., Young, L., Hawes, D., Giuliano, A., McNamara, G., et al. (2006). Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clinical Cancer Research, 12, 5615–5621.PubMedCrossRef

46.

Aktas, B., Tewes, M., Fehm, T., Hauch, S., Kimmig, R., & Kasimir-Bauer, S. (2009). Stem cell and epithelial–mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Research, 11(4), R46.PubMedCrossRef

47.

Theodoropoulos, P. A., Polioudaki, H., Agelaki, S., Kallergi, G., Saridaki, Z., Mavroudis, D., & Georgoulias, V. (2010). Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Letters, 288(1), 99–106.PubMedCrossRef

48.

Raimondi, C., Gradilone, A., Naso, G., Vincenzi, B., Petracca, A., Nicolazzo, C., Palazzo, A., Saltarelli, R., Spremberg, F., Cortesi, E., & Gazzaniga, P. (2011). Epithelial–mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Research and Treatment, 130(2), 449–455.PubMedCrossRef

49.

Gradilone, A., Raimondi, C., Nicolazzo, C., Petracca, A., Gandini, O., Vincenzi, B., Naso, G., Aglianò, A. M., Cortesi, E., & Gazzaniga, P. (2011). Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. Journal of Cellular and Molecular Medicine, 15(5), 1066–1070.PubMedCrossRef

50.

Armstrong, A. J., Marengo, M. S., Oltean, S., Kemeny, G., Bitting, R. L., Turnbull, J. D., Herold, C. I., Marcom, P. K., George, D. J., & Garcia-Blanco, M. A. (2011). Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research, 9(8), 997–1007.PubMedCrossRef

51.

Strati, A., Markou, A., Parisi, C., Politaki, E., Mavroudis, D., Georgoulias, V., & Lianidou, E. (2011). Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer, 11, 422.PubMedCrossRef

52.

Markou, A., Strati, A., Malamos, N., Georgoulias, V., & Lianidou, E. S. (2011). Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clinical Chemistry, 57(3), 421–430.PubMedCrossRef

53.

Kallergi, G., Papadaki, M. A., Politaki, E., Mavroudis, D., Georgoulias, V., & Agelaki, S. (2011). Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Research, 13(3), R59.PubMedCrossRef

54.

Payne, R. E., Yagüe, E., Slade, M. J., Apostolopoulos, C., Jiao, L. R., Ward, B., Coombes, R. C., & Stebbing, J. (2009). Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics, 10(1), 51–57.PubMedCrossRef

55.

Liu, Z., Fusi, A., Schmittel, A., Tinhofer, I., Schneider, A., & Keilholz, U. (2010). Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Cancer Biology & Therapy, 10(9), 860–864.CrossRef

56.

Kallergi, G., Mavroudis, D., Georgoulias, V., & Stournaras, C. (2007). Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Molecular Medicine, 13(1-2), 79–88.PubMedCrossRef

57.

Kallergi, G., Agelaki, S., Kalykaki, A., Stournaras, C., Mavroudis, D., & Georgoulias, V. (2008). Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Research, 10(5), R80.PubMedCrossRef

58.

Kasimir-Bauer, S., Hoffmann, O., Wallwiener, D., Kimmig, R., & Fehm, T. (2012). Expression of stem cell and epithelial–mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Research, 14(1), R15.PubMedCrossRef

59.

Ntoulia, M., Stathopoulou, A., Ignatiadis, M., Malamos, N., Mavroudis, D., Georgoulias, V., et al. (2006). Detection of mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clinical Biochemistry, 39, 879–887.PubMedCrossRef

60.

Zehentner, B. K., Secrist, H., Hayes, D. C., Zhang, X., Ostenson, R. C., Loop, S., Goodman, G., Houghton, R. L., & Persing, D. H. (2006). Detection of circulating tumor cells in peripheral blood of breast cancer patients during or after therapy using a multigene real-time RT-PCR assay. Molecular Diagnosis & Therapy, 10(1), 41–47.CrossRef

61.

Roncella, S., Ferro, P., Bacigalupo, B., Pronzato, P., Tognoni, A., Falco, E., Gianquinto, D., Ansaldo, V., Dessanti, P., Fais, F., Rosai, J., & Fedeli, F. (2005). Human mammaglobin mRNA is a reliable molecular marker for detecting occult breast cancer cells in peripheral blood. Journal of Experimental & Clinical Cancer Research, 24(2), 265–271.

62.

Marques, A. R., Teixeira, E., Diamond, J., Correia, H., Santos, S., Neto, L., Ribeiro, M., Miranda, A., & Passos-Coelho, J. L. (2009). Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence. Breast Cancer Research and Treatment, 114(2), 223–232.PubMedCrossRef

63.

Reinholz, M. M., Kitzmann, K. A., Tenner, K., Hillman, D., Dueck, A. C., Hobday, T. J., Northfelt, D. W., Moreno-Aspitia, A., Roy, V., Laplant, B., Allred, J. B., Stella, P. J., Lingle, W. L., & Perez, E. A. (2011). Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in north central cancer treatment group trials, n0234/336/436/437. Clinical Cancer Research, 17(22), 7183–7193.PubMedCrossRef

64.

Chimonidou, M., Strati, A., Tzitzira, A., Sotiropoulou, G., Malamos, N., Georgoulias, V., & Lianidou, E. S. (2011). DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clinical Chemistry, 57(8), 1169–1177.PubMedCrossRef

65.

Sotiropoulou, G., Anisowicz, A., & Sager, R. (1997). Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. Journal of Biological Chemistry, 272, 903–910.PubMedCrossRef

66.

Kioulafa, M., Balkouranidou, I., Sotiropoulou, G., Kaklamanis, L., Mavroudis, D., Georgoulias, V., & Lianidou, E. (2009). Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. International Journal of Cancer, 125, 2887–2892.CrossRef

67.

Phadke, P. A., Vaidya, K. S., Nash, K. T., Hurst, D. R., & Welch, D. R. (2008). BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. American Journal of Pathology, 172, 809–817.PubMedCrossRef

68.

Hurst, D. R., Edmonds, M. D., Scott, G. K., Benz, C. C., Vaidya, K. S., & Welch, D. R. (2009). Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Research, 69, 1279–1283.PubMedCrossRef

69.

Du, Y. C., Oshima, H., Oguma, K., Kitamura, T., Itadani, H., Fujimura, T., et al. (2009). Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology, 137, 1346–1357.PubMedCrossRef

70.

Gazzaniga, P., Naso, G., Gradilone, A., Cortesi, E., Gandini, O., Gianni, W., et al. (2010). Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. International Journal of Cancer, 126, 2437–2447.

71.

Gradilone, A., Naso, G., Raimondi, C., Cortesi, E., Gandini, O., Vincenzi, B., et al. (2011). Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Annals of Oncology, 22, 86–92.PubMedCrossRef

72.

Nakamura, S., Yagata, H., Ohno, S., Yamaguchi, H., Iwata, H., Tsunoda, N., et al. (2010). Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Br Cancer, 17, 199–204.CrossRef

73.

Serrano, M. J., Sánchez-Rovira, P., Delgado-Rodriguez, M., & Gaforio, J. J. (2009). Detection of circulating tumor cells in the context of treatment: prognostic value in breast cancer. Cancer Biology & Therapy, 8, 671–675.CrossRef

74.

Georgoulias, V. et al. (2012). Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Annals of Oncology. doi:10.1093/annonc/mds020.

75.

Pachmann, K., Camara, O., Kroll, T., Gajda, M., Gellner, A. K., Wotschadlo, J., & Runnebaum, I. B. (2011). Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “liquid biopsy”: trastuzumab in HER2/neu-positive breast carcinoma. Journal of Cancer Research and Clinical Oncology, 137(9), 1317–1327.PubMedCrossRef

76.

Hayashi, N., Nakamura, S., Tokuda, Y., Shimoda, Y., Yagata, H., Yoshida, A., Ota, H., Hortobagyi, G. N., Cristofanilli, M., & Ueno, N. T. (2011). Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. International Journal of Clinical Oncology, 17, 96–104.PubMedCrossRef

77.

Fehm, T., Müller, V., Alix-Panabières, C., & Pantel, K. (2008). Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Research, 10(Suppl 1), S1.PubMedCrossRef

78.

Kim, M. Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H., Norton, L., et al. (2009). Tumor self-seeding by circulating cancer cells. Cell, 139, 1315–1326.PubMedCrossRef

79.

Mego, M., Mani, S. A., & Cristofanilli, M. (2010). Molecular mechanisms of metastasis in breast cancer—clinical applications. Nature Reviews. Clinical Oncology, 7, 693–701.PubMedCrossRef

80.

Riethdorf, S., & Pantel, K. (2010). Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Annals of the New York Academy of Sciences, 1210, 66–77.PubMedCrossRef

81.

Kasimir-Bauer, S. (2009). Circulating tumor cells as markers for cancer risk assessment and treatment monitoring. Molecular Diagnosis & Therapy, 13, 209–215.CrossRef

82.

Lianidou, E. S. (2012). Circulating tumor cells—new challenges ahead (editorial). Clinical Chemistry, 58, 5.CrossRef

Title: Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment
Authors: Evi S. Lianidou
Athina Markou
Areti Strati
Publication date: 01-12-2012
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 3-4/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-012-9366-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3-4/2012

MDM2 binding protein, a novel metastasis suppressor

TGF-β signalling and its role in cancer progression and metastasis

Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment

The role of FOXP3 in the development and metastatic spread of breast cancer

Preface

EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer